Stock ACRS ACLARIS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Aclaris Therapeutics, Inc.

Equities

ACRS

US00461U1051

Market Closed - Nasdaq
Other stock markets
 21:00:00 30/04/2024 BST 		5-day change 1st Jan Change
1.21 USD -0.82% Intraday chart for Aclaris Therapeutics, Inc. -0.82% +15.24%
03-19 Aclaris Therapeutics, Inc. Announces Board Resignations CI
02-27 Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
AQ
FLARE THERAPEUTICS APPOINTS DOUGLAS MANION, M.D., FRCP AS CHIEF EXECUTIVE OFFICER
AQ
Aclaris: Q4 Earnings Snapshot
AQ
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
AQ
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
AQ
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
AQ
Aclaris Therapeutics Provides Corporate Update
AQ
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
AQ
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
AQ
Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Aclaris: Q3 Earnings Snapshot
AQ
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
AQ
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis
AQ
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
AQ
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
AQ
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
AQ
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
AQ
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)
AQ
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
AQ
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACRS Stock
  4. News Aclaris Therapeutics, Inc.
  5. Press Releases